- Home
- GENK vs BIVI Comparison
GENK vs BIVI Comparison
Compare GENK & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | BIVI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.5M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GENK | BIVI |
|---|---|---|
| Price | $1.54 | $1.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 47.0K | ★ 53.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $15.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $0.82 |
| 52 Week High | $4.98 | $9.09 |
Technical Indicators
Market Signals| Indicator | GENK | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 61.62 |
| Support Level | $1.46 | $1.52 |
| Resistance Level | $2.55 | $1.68 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 28.95 | 94.08 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.